Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 85
Selected: 0
NCT IDTitle
NCT00496873Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
NCT05456269A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
NCT04466514A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
NCT04655755Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT00504205MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
NCT00005871Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
NCT00005872Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
NCT03603964Guadecitabine Extension Study
NCT01627054A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
NCT00201721Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
NCT04134884Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
NCT05007873ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
NCT01357395A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
NCT04637009A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
NCT04953923Thorough QT Assessment of Cedazuridine in Healthy Subjects
NCT00894894Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
NCT01145989A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
NCT03922555ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
NCT03875287Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
NCT04479800Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
NCT06191978A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT01685268A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
NCT05082259ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
NCT02348489SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
NCT01896856Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
NCT01261312SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
NCT03913455Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
NCT03075826A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
NCT00571662Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
NCT01696032SGI-110 in Combination With Carboplatin in Ovarian Cancer
NCT00032773Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
NCT00878423Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
NCT03220477Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
NCT00113113Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
NCT04411030A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
NCT06802146Early Intervention in High Risk CCUS
NCT04250246A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1
NCT00005877Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
NCT04857645ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
NCT01752933SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
NCT02901899Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00005870Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
NCT03576963Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
NCT00042016Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042003Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT05245682Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
NCT00005873Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT02920008Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
NCT03813186Effect of Food on Blood Levels of ASTX727
NCT05360160A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)